Last reviewed · How we verify

NCT03520868

Heparin Requirements in Patients Undergoing Atrial Fibrillation Ablation on Coumadin vs NOACs

Completed Last updated 16 July 2021
What this trial tests

trial testing Monitoring Anti Factor Xa level in Atrial Fibrillation in 60 participants. Completed in 30 March 2020.

Timeline
5 May 2017
Primary endpoint
30 March 2020
30 March 2020

Quick facts

Lead sponsorSteward St. Elizabeth's Medical Center of Boston, Inc.
StatusCompleted
Study typeOBSERVATIONAL
Enrollment60
Start date5 May 2017
Primary completion30 March 2020
Estimated completion30 March 2020
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Steward St. Elizabeth's Medical Center of Boston, Inc.

Who can join

18 and older, any sex, with Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To observe, using a prospectively designed study, the effect of type of oral anticoagulant on intra-procedural heparin requirements in patients undergoing Atrial Fibrillation ablation and to assess whether ACT assay accurately reflects heparin anti coagulation effect.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

Other Steward St. Elizabeth's Medical Center of Boston, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03520868.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing